In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...
U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...
Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...
March 10 (Reuters) - German COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion ...
Hosted on MSN3mon
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlementPenn will receive $467 million under a settlement with German drug manufacturer BioNTech, which partnered with Pfizer to develop a COVID vaccine that relied on mRNA technology developed at the ...
Among the largest underlying components of FNDF, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, BioNTech SE (Symbol: BNTX) is down about 6.9%, and Ferguson Enterprises Inc (Symbol ...
March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday ...
The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...
BioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. The German developer of RNA vaccines and immunotherapies logged a profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback